Prediction of Rifampicin Resistance Beyond the RRDR Using Structure-based Machine Learning Approaches

Overview

Journal Sci Rep

Specialty Science

Date 2020 Oct 23

PMID 33093532

Citations 26

Authors

Stephanie Portelli

Yoochan Myung

Nicholas Furnham

Sundeep Chaitanya Vedithi

Douglas E V Pires

David B Ascher

Affiliations

Soon will be listed here.

Abstract

Rifampicin resistance is a major therapeutic challenge, particularly in tuberculosis, leprosy, P. aeruginosa and S. aureus infections, where it develops via missense mutations in gene rpoB. Previously we have highlighted that these mutations reduce protein affinities within the RNA polymerase complex, subsequently reducing nucleic acid affinity. Here, we have used these insights to develop a computational rifampicin resistance predictor capable of identifying resistant mutations even outside the well-defined rifampicin resistance determining region (RRDR), using clinical M. tuberculosis sequencing information. Our tool successfully identified up to 90.9% of M. tuberculosis rpoB variants correctly, with sensitivity of 92.2%, specificity of 83.6% and MCC of 0.69, outperforming the current gold-standard GeneXpert-MTB/RIF. We show our model can be translated to other clinically relevant organisms: M. leprae, P. aeruginosa and S. aureus, despite weak sequence identity. Our method was implemented as an interactive tool, SUSPECT-RIF (StrUctural Susceptibility PrEdiCTion for RIFampicin), freely available at https://biosig.unimelb.edu.au/suspect_rif/ .

Citing Articles

The role of artificial intelligence and machine learning in predicting and combating antimicrobial resistance.

Bilal H, Khan M, Khan S, Shafiq M, Fang W, Khan R Comput Struct Biotechnol J. 2025; 27:423-439.

PMID: 39906157 PMC: 11791014. DOI: 10.1016/j.csbj.2025.01.006.

From Data to Decisions: Leveraging Artificial Intelligence and Machine Learning in Combating Antimicrobial Resistance - a Comprehensive Review.

de la Lastra J, Wardell S, Pal T, de la Fuente-Nunez C, Pletzer D J Med Syst. 2024; 48(1):71.

PMID: 39088151 PMC: 11294375. DOI: 10.1007/s10916-024-02089-5.

Phylogenetic Analysis and Comparative Genomics of Brucella abortus and Brucella melitensis Strains in Egypt.

Elrashedy A, Nayel M, Salama A, Zaghawa A, Abdelsalam N, Hasan M J Mol Evol. 2024; 92(3):338-357.

PMID: 38809331 PMC: 11169049. DOI: 10.1007/s00239-024-10173-0.

Tackling the Antimicrobial Resistance "Pandemic" with Machine Learning Tools: A Summary of Available Evidence.

Rusic D, Kumric M, Seselja Perisin A, Leskur D, Bukic J, Modun D Microorganisms. 2024; 12(5).

PMID: 38792673 PMC: 11123121. DOI: 10.3390/microorganisms12050842.

Engineering G protein-coupled receptors for stabilization.

Velloso J, de Sa A, Pires D, Ascher D Protein Sci. 2024; 33(6):e5000.

PMID: 38747401 PMC: 11094779. DOI: 10.1002/pro.5000.

References

Pires D, C de Melo-Minardi R, Dos Santos M, da Silveira C, Santoro M, Meira Jr W . Cutoff Scanning Matrix (CSM): structural classification and function prediction by protein inter-residue distance patterns. BMC Genomics. 2012; 12 Suppl 4:S12. PMC: 3287581. DOI: 10.1186/1471-2164-12-S4-S12. View

Karmakar M, Globan M, Fyfe J, Stinear T, Johnson P, Holmes N . Analysis of a Novel pncA Mutation for Susceptibility to Pyrazinamide Therapy. Am J Respir Crit Care Med. 2018; 198(4):541-544. PMC: 6118032. DOI: 10.1164/rccm.201712-2572LE. View

Coll F, Phelan J, Hill-Cawthorne G, Nair M, Mallard K, Ali S . Genome-wide analysis of multi- and extensively drug-resistant Mycobacterium tuberculosis. Nat Genet. 2018; 50(2):307-316. DOI: 10.1038/s41588-017-0029-0. View

Steiner A, Stucki D, Coscolla M, Borrell S, Gagneux S . KvarQ: targeted and direct variant calling from fastq reads of bacterial genomes. BMC Genomics. 2014; 15:881. PMC: 4197298. DOI: 10.1186/1471-2164-15-881. View

Phelan J, Coll F, McNerney R, Ascher D, Pires D, Furnham N . Mycobacterium tuberculosis whole genome sequencing and protein structure modelling provides insights into anti-tuberculosis drug resistance. BMC Med. 2016; 14:31. PMC: 4804620. DOI: 10.1186/s12916-016-0575-9. View

Rozewicki J, Li S, Amada K, Standley D, Katoh K . MAFFT-DASH: integrated protein sequence and structural alignment. Nucleic Acids Res. 2019; 47(W1):W5-W10. PMC: 6602451. DOI: 10.1093/nar/gkz342. View

Rose A, Bradley A, Valasatava Y, Duarte J, Prlic A, Rose P . NGL viewer: web-based molecular graphics for large complexes. Bioinformatics. 2018; 34(21):3755-3758. PMC: 6198858. DOI: 10.1093/bioinformatics/bty419. View

Higgins D, Sharp P . CLUSTAL: a package for performing multiple sequence alignment on a microcomputer. Gene. 1988; 73(1):237-44. DOI: 10.1016/0378-1119(88)90330-7. View

Yoshida S, Iwamoto T, Arikawa K, Sekizuka T, Kuroda M, Inoue Y . Bacterial population kinetics in heteroresistant Mycobacterium tuberculosis harbouring rare resistance-conferring mutations in gyrA and rpoB imply an epistatic interaction of mutations in a pre-XDR-TB patient. J Antimicrob Chemother. 2020; 75(7):1722-1725. DOI: 10.1093/jac/dkaa109. View

10.

Kohli M, Schiller I, Dendukuri N, Dheda K, Denkinger C, Schumacher S . Xpert MTB/RIF assay for extrapulmonary tuberculosis and rifampicin resistance. Cochrane Database Syst Rev. 2018; 8:CD012768. PMC: 6513199. DOI: 10.1002/14651858.CD012768.pub2. View

11.

Ashkenazy H, Abadi S, Martz E, Chay O, Mayrose I, Pupko T . ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules. Nucleic Acids Res. 2016; 44(W1):W344-50. PMC: 4987940. DOI: 10.1093/nar/gkw408. View

12.

Rosa P, DEspindula H, Melo A, Fontes A, Finardi A, Belone A . Emergence and Transmission of Drug-/Multidrug-resistant Mycobacterium leprae in a Former Leprosy Colony in the Brazilian Amazon. Clin Infect Dis. 2019; 70(10):2054-2061. PMC: 7201420. DOI: 10.1093/cid/ciz570. View

13.

Cambau E, Saunderson P, Matsuoka M, Cole S, Kai M, Suffys P . Antimicrobial resistance in leprosy: results of the first prospective open survey conducted by a WHO surveillance network for the period 2009-15. Clin Microbiol Infect. 2018; 24(12):1305-1310. PMC: 6286419. DOI: 10.1016/j.cmi.2018.02.022. View

14.

Park Y, Pacitto A, Bayliss T, Cleghorn L, Wang Z, Hartman T . Essential but Not Vulnerable: Indazole Sulfonamides Targeting Inosine Monophosphate Dehydrogenase as Potential Leads against Mycobacterium tuberculosis. ACS Infect Dis. 2016; 3(1):18-33. PMC: 5972394. DOI: 10.1021/acsinfecdis.6b00103. View

15.

Schleusener V, Koser C, Beckert P, Niemann S, Feuerriegel S . Mycobacterium tuberculosis resistance prediction and lineage classification from genome sequencing: comparison of automated analysis tools. Sci Rep. 2017; 7:46327. PMC: 7365310. DOI: 10.1038/srep46327. View

16.

Rodrigues C, Pires D, Ascher D . DynaMut: predicting the impact of mutations on protein conformation, flexibility and stability. Nucleic Acids Res. 2018; 46(W1):W350-W355. PMC: 6031064. DOI: 10.1093/nar/gky300. View

17.

Pires D, Chen J, Blundell T, Ascher D . In silico functional dissection of saturation mutagenesis: Interpreting the relationship between phenotypes and changes in protein stability, interactions and activity. Sci Rep. 2016; 6:19848. PMC: 4726175. DOI: 10.1038/srep19848. View

18.

Trapero A, Pacitto A, Singh V, Sabbah M, Coyne A, Mizrahi V . Fragment-Based Approach to Targeting Inosine-5'-monophosphate Dehydrogenase (IMPDH) from Mycobacterium tuberculosis. J Med Chem. 2018; 61(7):2806-2822. PMC: 5900554. DOI: 10.1021/acs.jmedchem.7b01622. View

19.

Vedithi S, Malhotra S, Das M, Daniel S, Kishore N, George A . Structural Implications of Mutations Conferring Rifampin Resistance in Mycobacterium leprae. Sci Rep. 2018; 8(1):5016. PMC: 5864748. DOI: 10.1038/s41598-018-23423-1. View

20.

Portelli S, Phelan J, Ascher D, Clark T, Furnham N . Understanding molecular consequences of putative drug resistant mutations in Mycobacterium tuberculosis. Sci Rep. 2018; 8(1):15356. PMC: 6193939. DOI: 10.1038/s41598-018-33370-6. View